Olema Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Olema Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($42.22M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($43.78M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($30.39M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($34.56M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.38M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($30.97M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($21.50M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.10M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($28.29M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($22.72M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($32.86M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($23.03M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($17.71M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($16.41M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($15.34M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($7.84M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.45M) | Aug 10, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($1.69M) | May 11, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($45.88M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($47.86M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($34.87M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($37.62M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($33.53M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($34.34M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($23.34M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.60M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($29.60M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($23.22M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($33.29M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($23.25M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($17.76M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($16.52M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($15.45M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($7.87M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.49M) | Aug 10, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($1.04M) | May 11, 2021 |